RBDCOV: the first clinical trial looking for a new COVID-19 vaccine is initiated

Back to the "News" list

The first Phase III clinical trial of HIPRA’s Covid-19 vaccine in immunocompromised people was initiated this week. One of the objectives is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus.

 

EATG is participating in RBDCOV, a project aiming to study a COVID-19 vaccine in children, adolescents and immunocompromised patients. Drawing from its experience in patients’ advocacy and representation, EATG is contributing to the studies through community insights and outreach.

 

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.

 

Find more information about the initiation of the first clinical trial of RBDCOV in this press release.

The RBDCOV project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101046118

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.